PATIENTS with coronary artery spasm usually respond to sublingual nitroglycerin (NTG),1 but occasionally, sublingual NTG is not completely effective in controlling manifestations of acute ischemia.2-Intravenous NTG may be more effective than sublingual NTG in promptly controlling coronary spasm and ischemia-related findings." Intracoronary NTG should provide an even higher concentration of NTG at the site of coronary arterial dilation. This route of administration, however, has had only limited use. Intracoronary NTG reverses obtruction in some patients with acute myocardial infarction' and refractory ergonovine-induced spasm.10 Clearly, the role of intracoronary NTG in coronary spasm needs further study.
PATIENTS with coronary artery spasm usually respond to sublingual nitroglycerin (NTG),1 but occasionally, sublingual NTG is not completely effective in controlling manifestations of acute ischemia.2-Intravenous NTG may be more effective than sublingual NTG in promptly controlling coronary spasm and ischemia-related findings." Intracoronary NTG should provide an even higher concentration of NTG at the site of coronary arterial dilation. This route of administration, however, has had only limited use. Intracoronary NTG reverses obtruction in some patients with acute myocardial infarction' and refractory ergonovine-induced spasm.10 Clearly, the role of intracoronary NTG in coronary spasm needs further study.
We report five patients with coronary artery spasm unresponsive to sublingual or i.v. NTG. In four of five cases, spasm occurred spontaneously. In all five cases, evidence for myocardial ischemia promptly resolved and reopacification of the vessel involved in spasm occurred after intracoronary NTG.
Methods

Patients
Five patients were evaluated to further define the basis for chest pain. All developed coronary spasm during catheterization that was unresponsive to sublingual or i.v. NTG.
Catheterization Studies
Without premedication, cardiac catheterization was performed with a #8 Sones catheter using techniques described elsewhere.11 Narrowings reported represent diameter reduction. No patient took calcium antagonists at the time of study. Sublingual NTG was given after crushing 0.4-mg tablets (Lilly A 45-year-old man, who had LAD and LCx bypass graft surgery 3 years ago for effort angina, recently noted rest pain episodes of increasing frequency. Effort tolerance was good. LV pressure was 130/6 mm Hg, with minimal anterolateral hypokinesis. The LAD and LCx were totally occluded proximally and filled by patent bypass grafts (table 1). The mid-LAD was subtotally occluded 0.5 cm distal to the bypass graft anastomosis. The occlusion persisted after sublingual NTG, 0.4 mg ( fig. 2A) , given for spontaneous angina. There was excellent retrograde LAD filling but poor opacification beyond the subtotal occlusion.
After 100 Ag of NTG were injected into the LAD bypass graft, the subtotal occlusion disappeared with good distal opacification ( fig. 2B ) without a change in blood pressure.
Discussion
Five patients with transient myocardial ischemia due to coronary spasm were unresponsive to systemic NTG administration. Each case responded to intracoronary NTG. Spasm occured in the RCA in patients I and 2 and in the LAD in patients [3] [4] [5] . In four patients, spasm was spontaneous and in patient 2 it occurred after ergonovine. In patients 1-3, previously patent coronary arteries, with what appeared to be physiologically important atherosclerotic narrowings, were not visualized during angina. In patient 4, spasm occurred in a vessel that appeared normal angiographically and in patient 5 in a normalappearing vessel filled by a patent vein graft. Although these occlusions persisted after systemic NTG, relatively small doses (25-100 Ag) of intracoronary NTG resulted in prompt relief of findings of ischemia and revisualization of the occluded artery. In patients 1 and 2, this resulted from reversal of spasm at a hemodynamically important atherosclerotic RCA obstruction. In the third case, direct LCA injection of NTG did not resolve the presumed LAD spasm. NTG was probably delivered to the low-resistance circumflex system and did not reach the LAD site of spasm.9 RCA injection of NTG, however, resulted in prompt reopacification of the LAD distal to the site of spasm with resolution of angina and ischemic ECG changes. The RCA injection of NTG appeared to dilate an RCA-to-LAD collateral network. So hemodynamic conditions now favored flow to the mid-distal LAD from the RCA collaterals instead of through the series of proximal LAD narrowings. Spasm involving angiographically normal portions of the LAD reversed when NTG was injected directly into the LCA in patient 4 and through a vein graft in patient 5. The mechanism responsible for failure to respond to systemic NTG is open to speculation. Systemic NTG could have contributed to persistent spasm. Vasodilation due to systemic NTG reduces LV wall tension, and thus, oxygen demand. Reflex changes mediated by autonomic stimulation occur secondary to pressure reduction. But parasympathetic or sympathetic stimulation may evoke coronary spasm.' Systemic NTG could also increase flow in LCA branches not involved with spasm.14' 16 In animals, increases in LCA flow trigger reflex cardiac sympathetic discharge. 16 The hypothesis that NTG-induced increases in coronary flow evoke autonomic discharges that cause coronary constriction could explain other coronary constriction responses seen after sublingual NTG.17' 1" Finally, blood flow reduction during spasm could simply prevent delivery of NTG to the vaso vasorum and smooth muscle at the spasm site.
Recently, in two patients with ergonovine-evoked coronary spasm unresponsive to sublingual or i.v. NTG, intracoronary NTG reversed the spasm.'0 Our patient 2 is the third reported case with ergonovineevoked spasm unresponsive to sublingual NTG but responsive to intracoronary NTG. Each case had spasm involving the RCA. Unlike the other two cases, our patient received only 0.05 mg of ergonovine. Ergonovine must be used with caution." 1 We believe that this test should be limited to the catheterization laboratory, where intracoronary NTG can be given.
The findings in our patients support other claims relative to the value of intracoronary NTG in control of refractory coronary spasm,'0 and emphasize the action of intracoronary NTG to reverse refractory spasm occurring spontaneously or evoked by ergonovine. Reversal of spasm occurred promptly after intracoronary NTG even when spasm did not respond to systemic NTG. More studies are needed to document the safety and effectiveness of intracoronary NTG.
